The selection of Standard of Care is still one of the hottest controversial topics in upper gastrointestinal tumours. In this ESMO Podcast series, experts debate about the pros and cons of each approach alongside with future perspectives, biomarkers and implication for patients’ selection.
Controversies in upper GI oncology: Liquid Biopsy
One of controversial topics in modern upper GI oncology is the use of liquid biopsies as a decision tool for personalised treatments. Today we are addressing this topic bringing on board the experience and point of view of two international experts in the field: Dr Filippo Pietrantonio, a clinician, and Dr Dominic Rothwell, a scientist.
Published in October 2023
Controversies in upper GI oncology: 1st line systemic treatment in MASLD-associated HCC
Dr Matthias Pinter, of the Medical University of Vienna, Austria, and Andrea Casadei Gardini, of University Vita-Salute San Raffaele, Milan, Italy, discuss with Dr Jeroen Dekervel, of UZ Leuven, Belgium, the merits of immunotherapy vs TKI in the first-line systemic treatment of MASLD-associated HCC.
Published in September 2023
Controversies in upper GI oncology: Maintenance treatment in pancreatic cancer
Dr Jeroen Dekervel, GI Oncologist, UZ Leuven, Belgium, presents a debate between Dr Eileen O’Reilly, Medical Oncologist, MSKCC, New York, and Dr Daniel Laheru, Medical Oncologist, Johns Hopkins, Baltimore, Maryland considering maintenance treatment in pancreatic cancer.
Published in April 2023
Controversies in upper GI oncology: First-line checkpoint inhibitor use in metastatic GEA
In this podcast, Dr. Angelica Petrillo interviews Dr. Steven Maron and Dr. Raghav Sundar about the following issue: First-line checkpoint inhibitor use in metastatic gastroesophageal adenocarcinoma (GEA): guided by PD-L1 combined positive score (CPS) or not? The two experts debate about the pros and cons of using PD-L1 CPS to select patients as well as future perspectives.
Published in March 2023
Controversies in upper GI oncology: Neoadjuvant CRT vs neoadjuvant CT in oesophageal adenocarcinoma
In this podcast, Dr Angelica Petrillo interviews Prof Hanneke WM van Laarhoven and Prof Sylvie Lorenzen about the best choice for neoadjuvant treatment for non-metastatic oesophageal adenocarcinoma: chemoradiotherapy or chemotherapy? The two experts debate about the pros and cons of each approach alongside with future perspectives, biomarkers and implication for patients’ selection.
Published in September 2022